Open Access
Article
EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives
Nicola A Colabufo1,Marialessandra Contino1,Mauro Niso1,Francesco Berardi1,Marcello Leopoldo1,Roberto Perrone1
1
Dipartimento Farmacochimico, Universita degli Studi di Bari, A Moro, via Orabona, 4, 70125 Bari, Italy. colabufo@farmchim.uniba.it
DOI: 10.2741/3823 Volume 16 Issue 5, pp.1811-1823
Published: 01 January 2011
Abstract

Aim of present review is to provide an evidence-based update of mechanisms responsible for the onset of resistance to drug therapy by EGFR inhibitors, particularly with regards to TKIs. Among ABC transporters involved in MDR, P-glycoprotein and BCRP have been considered the pumps responsible for TKIs treatment failure. Moreover, two subtypes of EGFR mutations have been described: mutations of the exons coding for tyrosine kinase domain (18 to 21) and truncating mutations (exons 2 to 7) that involve downstream effectors such as MAPK, PI3K/Akt, STAT. The first group of mutations can be considered as a hallmark of NSCLC and are responsible for the failure of TKIs while the second group of mutations leads to resistance. The strategies to overcome MDR and to bypass the kinase domain mutations have been addressed. Finally, for some first generation TKIs some perspectives as radiotracers for PET/SPECT diagnosis in tumor displaying P-gp and BCRP overexpression have been suggested.

Share and Cite
Nicola A Colabufo, Marialessandra Contino, Mauro Niso, Francesco Berardi, Marcello Leopoldo, Roberto Perrone. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in Bioscience-Landmark. 2011. 16(5); 1811-1823.